These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

265 related items for PubMed ID: 33571795

  • 1. Comments to Drs. Bahji, Vazquez, and Zarate.
    Drevets WC, Popova V, Daly EJ, Borentain S, Lane R, Cepeda MS, Mathews M, Manji HK, Canuso CM.
    J Affect Disord; 2021 Mar 15; 283():262-264. PubMed ID: 33571795
    [Abstract] [Full Text] [Related]

  • 2. Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study.
    Popova V, Daly EJ, Trivedi M, Cooper K, Lane R, Lim P, Mazzucco C, Hough D, Thase ME, Shelton RC, Molero P, Vieta E, Bajbouj M, Manji H, Drevets WC, Singh JB.
    Am J Psychiatry; 2019 Jun 01; 176(6):428-438. PubMed ID: 31109201
    [Abstract] [Full Text] [Related]

  • 3. Efficacy of Esketamine Augmentation in Major Depressive Disorder: A Meta-Analysis.
    Papakostas GI, Salloum NC, Hock RS, Jha MK, Murrough JW, Mathew SJ, Iosifescu DV, Fava M.
    J Clin Psychiatry; 2020 May 26; 81(4):. PubMed ID: 32459407
    [Abstract] [Full Text] [Related]

  • 4. Synthesizing the Evidence for Ketamine and Esketamine in Treatment-Resistant Depression: An International Expert Opinion on the Available Evidence and Implementation.
    McIntyre RS, Rosenblat JD, Nemeroff CB, Sanacora G, Murrough JW, Berk M, Brietzke E, Dodd S, Gorwood P, Ho R, Iosifescu DV, Lopez Jaramillo C, Kasper S, Kratiuk K, Lee JG, Lee Y, Lui LMW, Mansur RB, Papakostas GI, Subramaniapillai M, Thase M, Vieta E, Young AH, Zarate CA, Stahl S.
    Am J Psychiatry; 2021 May 01; 178(5):383-399. PubMed ID: 33726522
    [Abstract] [Full Text] [Related]

  • 5. Treatment Response of Add-On Esketamine Nasal Spray in Resistant Major Depression in Relation to Add-On Second-Generation Antipsychotic Treatment.
    Dold M, Bartova L, Kasper S.
    Int J Neuropsychopharmacol; 2020 Jul 29; 23(7):440-445. PubMed ID: 32570275
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder.
    Kryst J, Kawalec P, Pilc A.
    Expert Opin Pharmacother; 2020 Jan 29; 21(1):9-20. PubMed ID: 31663783
    [Abstract] [Full Text] [Related]

  • 7. The effect of intravenous, intranasal, and oral ketamine in mood disorders: A meta-analysis.
    McIntyre RS, Carvalho IP, Lui LMW, Majeed A, Masand PS, Gill H, Rodrigues NB, Lipsitz O, Coles AC, Lee Y, Tamura JK, Iacobucci M, Phan L, Nasri F, Singhal N, Wong ER, Subramaniapillai M, Mansur R, Ho R, Lam RW, Rosenblat JD.
    J Affect Disord; 2020 Nov 01; 276():576-584. PubMed ID: 32871689
    [Abstract] [Full Text] [Related]

  • 8. Response to a recently published systematic review on intranasal esketamine for major depressive disorder.
    David S.
    J Affect Disord; 2020 Aug 01; 273():16-17. PubMed ID: 32421597
    [Abstract] [Full Text] [Related]

  • 9. Oral esketamine for treatment-resistant depression: rationale and design of a randomized controlled trial.
    Smith-Apeldoorn SY, Veraart JKE, Kamphuis J, van Asselt ADI, Touw DJ, Aan Het Rot M, Schoevers RA.
    BMC Psychiatry; 2019 Nov 29; 19(1):375. PubMed ID: 31783823
    [Abstract] [Full Text] [Related]

  • 10. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE.
    Bobo WV, Vande Voort JL, Croarkin PE, Leung JG, Tye SJ, Frye MA.
    Depress Anxiety; 2016 Aug 29; 33(8):698-710. PubMed ID: 27062450
    [Abstract] [Full Text] [Related]

  • 11. Intranasal esketamine: From origins to future implications in treatment-resistant depression.
    Sanders B, Brula AQ.
    J Psychiatr Res; 2021 May 29; 137():29-35. PubMed ID: 33647726
    [Abstract] [Full Text] [Related]

  • 12. Managing Esketamine Treatment Frequency Toward Successful Outcomes: Analysis of Phase 3 Data.
    Nijs M, Wajs E, Aluisio L, Turkoz I, Daly E, Janik A, Borentain S, Singh JB, DiBernardo A, Wiegand F.
    Int J Neuropsychopharmacol; 2020 Jul 29; 23(7):426-433. PubMed ID: 32270176
    [Abstract] [Full Text] [Related]

  • 13. Ketamine for treatment-resistant depression: ready or not for clinical use?
    Rush AJ.
    Am J Psychiatry; 2013 Oct 29; 170(10):1079-81. PubMed ID: 23982324
    [No Abstract] [Full Text] [Related]

  • 14. Esketamine for treatment resistant depression.
    Swainson J, Thomas RK, Archer S, Chrenek C, MacKay MA, Baker G, Dursun S, Klassen LJ, Chokka P, Demas ML.
    Expert Rev Neurother; 2019 Oct 29; 19(10):899-911. PubMed ID: 31282772
    [Abstract] [Full Text] [Related]

  • 15. Compounded intranasal racemic ketamine for major depressive disorder: A case report.
    Ziegler L, Peters E, Wanson A, Halpape K.
    Exp Clin Psychopharmacol; 2021 Dec 29; 29(6):750-754. PubMed ID: 33661659
    [Abstract] [Full Text] [Related]

  • 16. Esketamine for treatment resistant depression: a trick of smoke and mirrors?
    Gastaldon C, Papola D, Ostuzzi G, Barbui C.
    Epidemiol Psychiatr Sci; 2019 Dec 16; 29():e79. PubMed ID: 31841104
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial.
    Daly EJ, Singh JB, Fedgchin M, Cooper K, Lim P, Shelton RC, Thase ME, Winokur A, Van Nueten L, Manji H, Drevets WC.
    JAMA Psychiatry; 2018 Feb 01; 75(2):139-148. PubMed ID: 29282469
    [Abstract] [Full Text] [Related]

  • 18. Esketamine as a treatment for paediatric depression: questions of safety and efficacy.
    Zimmermann KS, Richardson R, Baker KD.
    Lancet Psychiatry; 2020 Oct 01; 7(10):827-829. PubMed ID: 31952957
    [No Abstract] [Full Text] [Related]

  • 19. Ketamine as an alternative treatment for treatment-resistant depression.
    Dowben JS, Grant JS, Keltner NL.
    Perspect Psychiatr Care; 2013 Jan 01; 49(1):2-4. PubMed ID: 23293991
    [No Abstract] [Full Text] [Related]

  • 20. Esketamine: A Novel Option for Treatment-Resistant Depression.
    Bozymski KM, Crouse EL, Titus-Lay EN, Ott CA, Nofziger JL, Kirkwood CK.
    Ann Pharmacother; 2020 Jun 01; 54(6):567-576. PubMed ID: 31795735
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.